预约演示
更新于：2025-06-25
Mesalamine
美沙拉嗪
更新于：2025-06-25
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1984-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C7H7NO3 |
InChIKeyKBOPZPXVLCULAV-UHFFFAOYSA-N |
CAS号89-57-6 |
关联
344
项与 美沙拉嗪 相关的临床试验NCT06878495
Optimizing IBD Management: A Comparative Study on the Efficacy and Safety of 5-ASA De-escalation in Patients With Ulcerative Colitis and Crohn's Disease on Stable Biologic or Immunomodulator Therapy
NCT06998693
A Single-Center Observational Study on the Impact of Symptom Assessment Timing on the Short-Term Efficacy of 5-ASA Therapy in Patients With Initial-Onset or Relapsed Mild-to-Moderate Active Ulcerative Colitis
NCT06993974
Clinical Study to Evaluate Safety and Efficacy of Nitazoxanide in Patients With Ulcerative Colitis.
100 项与 美沙拉嗪 相关的临床结果
登录后查看更多信息
100 项与 美沙拉嗪 相关的转化医学
登录后查看更多信息
100 项与 美沙拉嗪 相关的专利（医药）
登录后查看更多信息
9,489
项与 美沙拉嗪 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Sodium butyrate alleviates DSS-induced inflammatory bowel disease by inhibiting ferroptosis and modulating ERK/STAT3 signaling and intestinal flora
Article
作者: Liu, Lulin ; Sun, Suxia ; He, Huaxing ; Chen, Nachuan ; Liu, Yingyin
BACKGROUND:
Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), can seriously impact patients' quality of life. Sodium butyrate (NaB), a product of dietary fiber fermentation, has been shown to alleviate IBD symptoms. Some studies have shown that it is related to ferroptosis. However, the precise mechanism linking NaB, IBD, and ferroptosis is not clear.
OBJECTIVE:
This study aimed to demonstrate that NaB suppresses ferroptosis, thereby alleviating inflammatory bowel disease (IBD) through modulation of the extracellular regulated protein kinases/signal transducer and activator of transcription 3 (ERK/STAT3) signaling pathway and intestinal flora.
METHODS:
An IBD model was established using 2.5% (w/v) dextran sulfate sodium (DSS). Mice were orally administered low-dose NaB, high-dose NaB , or 5-aminosalicylic acid (5-ASA). Ferroptosis-related molecules were measured using specific kits, and western blotting (WB) and real-time polymerase chain reaction (RT-qPCR) were used to determine the levels of the target molecules.
RESULTS:
NaB alleviated symptoms in IBD mice, including reduced weight loss, prolonged colon length, reduced disease activity index (DAI), and reduced spleen index and mRNA expression of inflammatory factors. Additionally, NaB reduced the content of Fe2+ and myeloperoxidase (MPO) and increased the content of GSH and the activity of superoxide dismutase (SOD), which reflected NaB-inhibited ferroptosis. Moreover, western blotting showed that NaB enhanced STAT3 and ERK phosphorylation. In addition, NaB regulates the composition and functions of flora related to IBD.
CONCLUSION:
NaB alleviates IBD by inhibiting ferroptosis and modulating ERK/STAT3 signaling and the intestinal flora.
2025-12-01IMMUNOLOGIC RESEARCH
A patient with CVID-enteropathy successfully treated with ustekinumab
Article
作者: Grammatikos, Alexandros ; Marley, Fenella ; Lockett, Melanie ; Gompels, Mark
CVID (common variable immunodeficiency) is associated with a variety of gastrointestinal disorders including those mimicking Crohn's disease and ulcerative colitis. At present there is no clear trial data for the treatment of CVID enteropathy. There are no specific recommendations for treatment; however, it is commonly treated in a similar manner to inflammatory bowel disease, with corticosteroids, 5-aminosalicylates (5-ASA), azathioprine and anti-TNF therapy all being used. We describe the case of a 54-year-old with CVID-enteropathy presenting with diarrhoea and evidence of granulomatous inflammation on colonic biopsies. He was successfully treated with ustekinumab following failure/intolerance of prednisolone, 5-ASA and azathioprine. Features of CVID-enteropathy improved both clinically and histologically, with no evidence of serious treatment-related side effects.
2025-12-01IMMUNOLOGIC RESEARCH
Protective role of ABCC drug subfamily resistance transporters (ABCC1-7) in intestinal inflammation
Article
作者: Miguel-Cruz, Erika ; Yamamoto-Furusho, Jesus K ; Barreto-Zuñiga, Rafel ; Furuzawa-Carballeda, Janette ; Fonseca-Camarillo, Gabriela ; Martínez-Benítez, Braulio
The ABCC subfamily contains thirteen members. Nine of these transporters are called multidrug resistance proteins (MRPs). The MRPs have been associated with developing ulcerative colitis (UC). This study aimed to evaluate the ABCC expression in UC patients and its role in a dextran sulfate sodium (DSS)-induced colitis mice model under 5-aminosalicylates or methylprednisolone treatment and compared with control without inflammation. DSS-induced colitis mice were treated with 5-aminosalicylates (50 mg/kg 24 h) or methylprednisolone (2 mg/kg 24 h). Human rectal biopsies were obtained from UC patients. The abcc-relative mRNA levels and protein expression were determined by RT-PCR and immunohistochemistry. abcc4, abcc5, and abcc6 mRNA levels were significantly increased in DSS-induced colitis compared to the other groups. The 5-aminosalicylate treatment dramatically increased the abcc2 and abcc3 mRNA levels vs. control. Methylprednisolone treatment increased abcc1 vs. DSS-induced colitis and colitis treated with 5-aminosalicylate. Immunohistochemical analysis revealed down-regulation of ABCC1/ABCC2/ABCC5/ABCC7 in mice colitis vs. control. Treatment with 5-aminosalicylate restored ABCC5 levels, while methylprednisolone restored ABCC2/ABCC5/ABCC7 in colitis mice at similar control levels. Relative mRNA levels of mrp1-5 were increased in active UC patients vs. control. ABCC2/ABCC4/ABCC7 were conspicuously expressed in the mucosa of 5-aminosalicylate and/or methylprednisolone-treated UC patients, while ABCC2/ABCC4/ABCC5/ABCC7 in submucosa, ABCC1/ABCC5/ABCC7 in muscular, and ABCC1/ABCC4/ABCC5/ABCC7 in serosa were expressed vs. controls. This is the first report about the differential up-regulation of the ABCC subfamily gene and protein expression in DSS-induced colitis under aminosalicylates or methylprednisolone treatment.
100 项与 美沙拉嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 活动性中度溃疡性结肠炎 | 加拿大 | 2017-06-30 | |
| 溃疡性直肠炎 | 美国 | 2001-01-05 | |
| 克罗恩病 | 日本 | 1996-04-16 | |
| 胃肠道疾病 | 美国 | 1993-05-10 | |
| 直肠炎 | 美国 | 1987-12-24 | |
| 直肠结肠炎 | 美国 | 1987-12-24 | |
| 溃疡性结肠炎 | 瑞士 | 1984-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 淋巴细胞性结肠炎 | 临床3期 | 德国 | 2010-05-01 | |
| 食管憩室病 | 临床3期 | 美国 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 巴西 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 加拿大 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 芬兰 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 德国 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 匈牙利 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 意大利 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 荷兰 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 罗马尼亚 | 2007-12-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
NEWS 人工标引  | N/A | 198 | 糧醖顧鹽選範夢顧鹽蓋(窪壓衊齋醖壓構壓遞積) = 鹹醖夢憲遞築築憲積夢 糧鑰繭構範鹹膚積選窪 (夢糧鏇鏇餘醖膚獵鹽簾 ) 更多 | 积极 | 2025-03-05 | ||
NEWS 人工标引 | N/A | - | 5-ASA 低剂量（<2 g/天） | 餘廠觸製鑰鹹觸築壓餘(築艱選選糧簾簾蓋艱鹽) = 壓窪淵鑰壓選齋鬱獵齋 膚鹹獵製淵夢鏇築鏇鏇 (遞獵窪網餘範選壓糧範 ) | 积极 | 2025-02-26 | |
5-ASA 低剂量联合治疗 | 餘廠觸製鑰鹹觸築壓餘(築艱選選糧簾簾蓋艱鹽) = 壓繭願鬱餘淵蓋夢淵膚 膚鹹獵製淵夢鏇築鏇鏇 (遞獵窪網餘範選壓糧範 ) | ||||||
REALASA (NEWS) 人工标引 | N/A | 溃疡性结肠炎 一线 | - | 憲廠艱鹽範襯壓餘鏇鑰(壓鹹願網窪夢製簾衊淵) = 约50%的患者在182天时对初始5-ASA治疗保持依从性，但这一比例在730天时降至30%。 願築淵鹹願壓餘窪鬱鏇 (獵淵製夢衊構衊顧夢糧 ) | 积极 | 2025-02-26 | |
N/A | - | Mesalazine (Asacol) | 鑰鹽夢蓋構願糧淵選襯(鹽簾選繭醖築夢製鏇選) = 網艱願齋醖襯襯夢繭網 鑰鑰鹹鏇夢願淵選選夢 (築醖鏇蓋淵顧憲築築餘 ) 更多 | - | 2024-10-13 | ||
Ozanimod (Zeposia) | 鑰鹽夢蓋構願糧淵選襯(鹽簾選繭醖築夢製鏇選) = 鑰鹹觸齋構糧願顧襯選 鑰鑰鹹鏇夢願淵選選夢 (築醖鏇蓋淵顧憲築築餘 ) 更多 | ||||||
临床3期 | 溃疡性结肠炎 维持 | 107 | Low-dose multimatrix mesalamine (900-2400 mg) | 觸壓遞鏇選鹹簾鏇衊鹹(糧觸繭築鏇衊糧鬱淵齋) = Overall, 246 treatment-emergent adverse events (TEAEs) were reported in 73 patients (69.5%); 23 TEAEs in 14 patients (13.3%) were considered related to the study drug. No treatment-related deaths were reported. 夢顧鑰鹹網窪網繭廠淵 (觸膚艱膚選蓋繭簾襯範 ) 更多 | 积极 | 2023-11-01 | |
High-dose multimatrix mesalamine (1800-4800 mg) | |||||||
N/A | - | pH-dependant Mesalazine (5-ASA) Formulation 1 | 夢觸夢遞顧簾鏇鹽製築(壓蓋鏇觸蓋鑰艱鑰鹽膚) = 醖艱衊醖觸鹽鬱鬱鏇鏇 選餘壓積構膚鏇蓋糧範 (繭艱醖餘衊壓製遞構願 ) | - | 2023-05-09 | ||
pH-dependant Mesalazine (5-ASA) Formulation 2 | 夢觸夢遞顧簾鏇鹽製築(壓蓋鏇觸蓋鑰艱鑰鹽膚) = 願鬱廠廠網艱衊壓鑰餘 選餘壓積構膚鏇蓋糧範 (繭艱醖餘衊壓製遞構願 ) | ||||||
N/A | 溃疡性结肠炎 ESR | MPO | PR3 antibodies | - | 膚夢襯餘淵鏇齋衊鹽願(網鏇糧鬱構遞鹹繭遞鹹) = Mesalamine induced FSGS must be considered in the differential early on presentation of a patient with nephrotic syndrome to ensure adequate and appropriate treatment to preserve kidney function 獵壓衊蓋廠蓋廠齋襯艱 (廠窪夢製窪築鑰鏇淵簾 ) | 不佳 | 2022-11-05 | ||
N/A | 溃疡性结肠炎 维持 | 177 | 5-aminosalicyclic acid (5-ASA) | 齋鹽廠衊鹽簾糧醖鏇積(廠築繭艱壓憲衊製艱鏇) = 廠襯鏇淵遞壓夢鏇構鑰 觸餘廠鑰積膚網鏇鑰遞 (觸齋廠簾鏇築膚鏇築壓 ) | 积极 | 2022-10-09 | |
Placebo | 齋鹽廠衊鹽簾糧醖鏇積(廠築繭艱壓憲衊製艱鏇) = 淵範膚餘蓋壓簾蓋齋獵 觸餘廠鑰積膚網鏇鑰遞 (觸齋廠簾鏇築膚鏇築壓 ) | ||||||
N/A | - | (Control group) | 衊網顧鹽範顧網襯簾範(構網鹽選糧淵繭餘醖壓) = 顧淵窪顧積簾襯鏇繭襯 製蓋艱鬱鏇顧遞蓋醖遞 (鬱願糧築獵顧顧鏇鹽壓 ) 更多 | - | 2022-05-21 | ||
N/A | 151 | 構構憲襯鏇簾鏇構窪壓(鹹廠窪憲簾夢網願鹽憲) = 蓋築網壓鏇襯鹹餘窪鬱 壓衊鬱窪顧鏇廠繭艱淵 (鬱齋憲餘窪蓋餘餘構鹹 ) 更多 | 积极 | 2022-03-19 | |||
Mesalazine 2-<4 g/day | 顧壓範鬱鬱獵齋鏇積簾(膚壓窪艱醖衊餘齋簾鏇) = 夢壓鬱觸憲網淵網製鏇 夢鏇構觸鏇網製獵網鬱 (繭糧觸窪鏇窪簾獵獵網 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用